BioMark Diagnostics【BUX】銘柄情報

BioMark Diagnostics Inc (BUX) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.55

( - )

買値

0.54

売値

0.55

出来高

平均取引量 (3 か月)

$ 1,177

財務取引量

0.00 日の範囲 0.00

0.27 52 週間の範囲 0.64

時価総額

58.566M

企業価値

53.751M

前日終値

0.55

始値

時刻

最終取引時間

VWAP

歳入

91.77k

純利益

-1.7M

発行済株式数

106,483,435

浮動株比率 (%)

45.71%

機関投資家保有比率 (%)

配当利回り

PER

-31.54

株価売上高倍率 (PSR)

591.96

1 株当たり利益 (EPS)

-0.02

ベータ

-0.32

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck canc... Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. 詳細を表示

セクター

業界

ウェブサイト

www.biomarkdiagnostics.com

本社

Richmond, Canada

設立

2026

BioMark Diagnostics Inc is listed in the sector of the Canadian Securities Exchange with ticker BUX. The last closing price for BioMark Diagnostics was $0.55. Over the last year, BioMark Diagnostics shares have traded in a share price range of $ 0.27 to $ 0.64.

BioMark Diagnostics currently has 106,483,435 shares in issue. The market capitalisation of BioMark Diagnostics is $58.57 million. BioMark Diagnostics has a price to earnings ratio (PE ratio) of -31.54.

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in...

BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the...

BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation...

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.01	1.85185185185	0.54	0.55	0.48	5600	0.53946429	CS
4	0.01	1.85185185185	0.54	0.55	0.48	3337	0.54519011	CS
12	-0.03	-5.1724137931	0.58	0.61	0.48	3901	0.56656081	CS
26	0.1	22.2222222222	0.45	0.64	0.45	7343	0.54442602	CS
52	0.205	59.4202898551	0.345	0.64	0.27	12160	0.4244172	CS
156	0.25	83.3333333333	0.3	0.64	0.17	13059	0.30890731	CS
260	0.32	139.130434783	0.23	0.64	0.15	15783	0.26936548	CS